Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1997-10-17
2001-06-26
Duffy, Patricia A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023700
Reexamination Certificate
active
06251872
ABSTRACT:
TECHNICAL FIELD
This invention relates to nucleic acid vaccines for rickettsial diseases of animals, including humans.
BACKGROUND OF THE INVENTION
The rickettsias are a group of small bacteria commonly transmitted by arthropod vectors to man and animals, in which they may cause serious disease. The pathogens causing human rickettsial diseases include the agent of epidemic typhus,
Rickettsia prowazekii,
which has resulted in the deaths of millions of people during wartime and natural disasters. The causative agents of spotted fever, e.g.,
Rickettsia rickettsii
and
Rickettsia conorii,
are also included within this group. Recently, new types of human rickettsial disease caused by members of the tribe Ehrlichiae have been described. Ehrlichiae infect leukocytes and endothelial cells of many different mammalian species, some of them causing serious human and veterinary diseases. Over 400 cases of human ehrlichiosis, including some fatalities, caused by
Ehrlichia chaffeensis
have now been reported. Clinical signs of human ehrlichiosis are similar to those of Rocky Mountain spotted fever, including fever, nausea, vomiting, headache, and rash.
Heartwater is another infectious disease caused by a rickettsial pathogen, namely
Cowdria ruminantium,
and is transmitted by ticks of the genus Amblyomma. The disease occurs throughout most of Africa and has an estimated endemic area of about 5 million square miles. In endemic areas, heartwater is a latent infection in indigenous breeds of cattle that have been subjected to centuries of natural selection. The problems occur where the disease contacts susceptible or naive cattle and other ruminants. Heartwater has been confirmed to be on the island of Guadeloupe in the Caribbean and is spreading through the Caribbean Islands. The tick vectors responsible for spreading this disease are already present on the American mainland and threaten the livestock industry in North and South America
In acute cases of heartwater, animals exhibit a sudden rise in temperature, signs of anorexia, cessation of rumination, and nervous symptoms including staggering, muscle twitching, and convulsions. Death usually occurs during these convulsions. Peracute cases of the disease occur where the animal collapses and dies in convulsions having shown no preliminary symptoms. Mortality is high in susceptible animals. Angora sheep infected with the disease have a 90% mortality rate while susceptible cattle strains have up to a 60% mortality rate.
If detected early, tetracycline or chloramphenicol treatment are effective against rickettsial infections, but symptoms are similar to numerous other infections and there are no satisfactory diagnostic tests (Helmick, C., K. Bernard, L. D'Angelo [1984]
J. Infect. Dis.
150:480).
Animals which have recovered from heartwater are resistant to further homologous, and in some cases heterologous, strain challenge. It has similarly been found that persons recovering from a rickettsial infection may develop a solid and lasting immunity. Individuals recovered from natural infections are often immune to multiple isolates and even species. For example, guinea pigs immunized with a recombinant
R. conorii
protein were partially protected even against
R. rickettsii
(Vishwanath, S., G. McDonald, N. Watkins [1990]
Infect. Immun.
58:646). It is known that there is structural variation in rickettsial antigens between different geographical isolates. Thus, a functional recombinant vaccine against multiple isolates would need to contain multiple epitopes, e.g. protective T and B cell epitopes, shared between isolates. It is believed that serum antibodies do not play a significant role in the mechanism of immunity against rickettsia (Uilenberg, G. [1983]
Advances in Vet. Sci. and Comp. Med
27:427-480; Du Plessis, Plessis, J. L. [1970]
Onderstepoort J. Vet. Res.
37(3):147-150).
Vaccines based on inactivated or attenuated rickettsiae have been developed against certain rickettsial diseases, for example against
R. prowazekii
and
R. rickettsii.
However, these vaccines have major problems or disadvantages, including undesirable toxic reactions, difficulty in standardization, and expense (Woodward, T. [1981] “Rickettsial diseases: certain unsettled problems in their historical perspective,” In
Rickettsia and Rickettsial Diseases
, W. Burgdorfer and R. Anacker, eds., Academic Press, New York, pp. 17-40).
A vaccine currently used in the control of heartwater is composed of live infected sheep blood. This vaccine also has several disadvantages. First, expertise is required for the intravenous inoculation techniques required to administer this vaccine. Second, vaccinated animals may experience shock and so require daily monitoring for a period after vaccination. There is a possibility of death due to shock throughout this monitoring period, and the drugs needed to treat any shock induced by vaccination are costly. Third, blood-borne parasites may be present in the blood vaccine and be transmitted to the vaccinates. Finally, the blood vaccine requires a cold chain to preserve the vaccine.
Clearly, a safer, more effective vaccine that is easily administered would be particularly advantageous. For these reasons, and with the advent of new methods in biotechnology, investigators have concentrated recently on the development of new types of vaccines, including recombinant vaccines. However, recombinant vaccine antigens must be carefully selected and presented to the immune system such that shared epitopes are recognized. These factors have contributed to the search for effective vaccines.
A protective vaccine against rickettsiae that elicits a complete immune response can be advantageous. A few antigens which potentially can be useful as vaccines have now been identified and sequenced for various pathogenic rickettsia. The genes encoding the antigens and that can be employed to recombinantly produce those antigen have also been identified and sequenced. Certain protective antigens identified for
R. rickettsii, R. conorii,
and
R. prowazekii
(e.g., rOmpA and rOmpB) are large (>100kDa), dependent on retention of native conformation for protective efficacy, but are often degraded when produced in recombinant systems. This presents technical and quality-control problems if purified recombinant proteins are to be included in a vaccine. The mode of presentation of a recombinant antigen to the immune system can also be an important factor in the immune response.
Nucleic acid vaccination has been shown to induce protective immune responses in non-viral systems and in diverse animal species (Special Conference Issue, WHO meeting on nucleic acid vaccines [1994]
Vaccine
12:1491). Nucleic acid vaccination has induced cytotoxic lymphocyte (CTL), T-helper
1
, and antibody responses, and has been shown to be protective against disease (Ulmer, J., J. Donelly, S. Parker et al. [1993]
Science
259:1745). For example, direct intramuscular injection of mice with DNA encoding the influenza nucleoprotein caused the production of high titer antibodies, nucleoprotein-specific CTLs, and protection against viral challenge. Immunization of mice with plasmid DNA encoding the Plasmodium yoelii circumsporozoite protein induced high antibody titers against malaria sporozoites and CTLs, and protection against challenge infection (Sedegah, M., R. Hedstrom, P. Hobart, S. Hoffman [1994]
Proc. Natl. Acad. Sci. USA
91:9866). Cattle immunized with plasmids encoding bovine herpesvirus 1 (BHV-1) glycoprotein IV developed neutralizing antibody and were partially protected (Cox, G., T. Zamb, L. Babiuk [1993]
J. Virol.
67:5664). However, it has been a question in the field of immunization whether the recently discovered technology of nucleic acid vaccines can provide improved protection against an antigenic drift variant. Moreover, it has not heretofore been recognized or suggested that nucleic acid vaccines may be successful to protect against rickettsial disease or that a m
Alleman Arthur Rick
Barbet Anthony F.
Bowie Michael V.
Burridge Michael J.
Ganta Roman Reddy
Duffy Patricia A.
Saliwanchik Lloyd & Saliwanchik
University of Florida
LandOfFree
Nucleic acid vaccines for ehrlichia chaffeensis and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid vaccines for ehrlichia chaffeensis and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid vaccines for ehrlichia chaffeensis and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2503866